News archive
Showing 717 results
August 2020
-
Media Release
Novartis PARALLAX data provides further evidence of the potential benefit of Entresto® in patients with HFpEF
PARALLAX met one of its co-primary endpoints, showing a significant reduction in NT-proBNP with Entresto (sacubitril/valsartan) compared to individualized medical therapy (IMT) at 12 weeks1; no… -
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
-
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164… -
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
-
Media Release
Novartis launches PsO in the Know podcast series hosted by music icon Cyndi Lauper
Podcast to feature 1:1 interviews conducted by Lauper with patients and advocates to address the impact psoriasis (PsO) can have on day-to-day life Guests to include real patient advocates and… -
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
Media Release
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Kesimpta delivers powerful efficacy with a favorable safety profile and can be self-administered at home, addressing significant unmet needs for people living with relapsing forms of multiple… -
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
-
Media Release
Novartis announces FDA filing acceptance of Xolair® (omalizumab) prefilled syringe for self-administration across all indications
If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and… -
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
-
Media Release
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis
Ofatumumab is a targeted B-cell therapy that delivers superior efficacy with a similar safety profile when compared with teriflunomide, a commonly prescribed oral treatment for multiple sclerosis¹…